NCT02514577View on ClinicalTrials.gov

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

November 7, 2015

Primary Completion Date

May 1, 2017

Study Completion Date

May 1, 2017

Conditions
Plaque Psoriasis
Interventions
DRUG

IDP-122 Lotion

Topical lotion

DRUG

IDP-122 Vehicle Lotion

Topical lotion. No active ingredient.

Trial Locations (15)

20847

Valeant Site 6, Rockville

27601

Valeant Site 9, Raleigh

30301

Valeant Site 13, Atlanta

37901

Valeant Site 5, Knoxville

48103

Valeant Site 4, Ann Arbor

48346

Valeant Site 8, Clarkston

71901

Valeant Site 11, Hot Springs

73301

Valeant Site 3, Austin

78201

Valeant Site 2, San Antonio

83701

Valeant Site 7, Boise

89101

Valeant Site 15, Las Vegas

91436

Valeant Site 10, Encino

92023

Valeant Site 1, Encinitas

95401

Valeant Site 12, Santa Rosa

99201

Valeant Site 14, Spokane

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02514577 - Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis | Biotech Hunter | Biotech Hunter